Skip to main content
Erschienen in: Supportive Care in Cancer 9/2019

30.05.2019 | Review Article

Cognitive rehabilitation for cancer-related cognitive dysfunction: a systematic review

verfasst von: Holly A. Fernandes, Nadine M. Richard, Kim Edelstein

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Individuals with non-central nervous system (CNS) cancers can experience cancer-related cognitive dysfunction (CRCD), negatively impacting daily functioning and quality of life. This systematic review examined cognitive rehabilitation programs aimed at improving cognitive function.

Methods

PsychInfo and PubMed were searched in February 2019. Eligible studies evaluated a cognitive rehabilitation program for adults with non-CNS cancers and included at least one objective cognitive measure. Across studies, we assessed methodological quality using relevant criteria based on published intervention-related review guidelines and examined findings from performance-based and self-reported outcome measures.

Results

19 studies met inclusion criteria, totalling 1124 participants altogether. These studies included randomized controlled trials (n = 12), partial, quasi or non-randomized controlled trials (n = 3) and single-arm pilot studies (n = 4). All studies found improvements on at least one cognitive measure (performance-based or self-reported). By cognitive domain, objective improvements in memory were most commonly reported, followed by executive functions and processing speed. In terms of methodological quality, studies generally provided clear descriptions of participants and interventions. However, limitations included lack of standardized terminology for interventions, discrepancies in outcome measures, and incomplete statistical reporting.

Conclusions

The available evidence supports clinical implementation of cognitive rehabilitation to improve CRCD, with further work in program development, dissemination, and feasibility recommended. We provide specific recommendations to facilitate future research and integration in this field.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Hodgson KD, Hutchinson AD, Wilson CJ, Nettelbeck T (2013) A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev 39(3):297–304PubMedCrossRef Hodgson KD, Hutchinson AD, Wilson CJ, Nettelbeck T (2013) A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev 39(3):297–304PubMedCrossRef
2.
Zurück zum Zitat Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Cancer 100(11):2292–2299PubMedCrossRef Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Cancer 100(11):2292–2299PubMedCrossRef
3.
Zurück zum Zitat Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier J-M, Eisenberg PD, Meerwaldt J (2004) Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22(1):157–165PubMedCrossRef Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier J-M, Eisenberg PD, Meerwaldt J (2004) Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22(1):157–165PubMedCrossRef
4.
Zurück zum Zitat Schagen SB, Klein M, Reijneveld J, Brain E, Deprez S, Joly F, Scherwath A, Schrauwen W, Wefel J (2014) Monitoring and optimising cognitive function in cancer patients: present knowledge and future directions. Eur J Cancer Suppl 12(1):29–40CrossRef Schagen SB, Klein M, Reijneveld J, Brain E, Deprez S, Joly F, Scherwath A, Schrauwen W, Wefel J (2014) Monitoring and optimising cognitive function in cancer patients: present knowledge and future directions. Eur J Cancer Suppl 12(1):29–40CrossRef
5.
Zurück zum Zitat Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, Van Dam FS (2006) Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 98(23):1742–1745PubMedCrossRef Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, Van Dam FS (2006) Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 98(23):1742–1745PubMedCrossRef
6.
Zurück zum Zitat Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS, Mulrooney TJ, Schwartz GN, Kaufman PA (2010) Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 28(29):4434–4440PubMedPubMedCentralCrossRef Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS, Mulrooney TJ, Schwartz GN, Kaufman PA (2010) Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 28(29):4434–4440PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS (2010) Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 28(8):1294–1300PubMedCrossRef Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS (2010) Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 28(8):1294–1300PubMedCrossRef
8.
Zurück zum Zitat Hermelink K, Bühner M, Sckopke P, Neufeld F, Kaste J, Voigt V, Münzel K, Wuerstlein R, Ditsch N, Hellerhoff K (2017) Chemotherapy and post-traumatic stress in the causation of cognitive dysfunction in breast cancer patients. J Natl Cancer Inst 109(10):djx057 Hermelink K, Bühner M, Sckopke P, Neufeld F, Kaste J, Voigt V, Münzel K, Wuerstlein R, Ditsch N, Hellerhoff K (2017) Chemotherapy and post-traumatic stress in the causation of cognitive dysfunction in breast cancer patients. J Natl Cancer Inst 109(10):djx057
9.
Zurück zum Zitat Schagen SB, Wefel JS (2017) Post-traumatic stress as the primary cause for cognitive decline—not the whole story, and perhaps no story at all. J Natl Cancer Inst 109(10) Schagen SB, Wefel JS (2017) Post-traumatic stress as the primary cause for cognitive decline—not the whole story, and perhaps no story at all. J Natl Cancer Inst 109(10)
11.
Zurück zum Zitat Janelsins MC, Kesler SR, Ahles TA, Morrow GR (2014) Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry 26(1):102–113PubMedPubMedCentralCrossRef Janelsins MC, Kesler SR, Ahles TA, Morrow GR (2014) Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry 26(1):102–113PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Zer A, Pond GR, Razak ARA, Tirona K, Gan HK, Chen EX, O’sullivan B, Waldron J, Goldstein DP, Weinreb I (2018) Association of neurocognitive deficits with radiotherapy or chemoradiotherapy for patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg 144(1):71–79PubMed Zer A, Pond GR, Razak ARA, Tirona K, Gan HK, Chen EX, O’sullivan B, Waldron J, Goldstein DP, Weinreb I (2018) Association of neurocognitive deficits with radiotherapy or chemoradiotherapy for patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg 144(1):71–79PubMed
13.
Zurück zum Zitat Alibhai SM, Timilshina N, Duff-Canning S, Breunis H, Tannock IF, Naglie G, Fleshner NE, Krahn MD, Warde P, Marzouk S (2017) Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer. Cancer 123(2):237–244PubMedCrossRef Alibhai SM, Timilshina N, Duff-Canning S, Breunis H, Tannock IF, Naglie G, Fleshner NE, Krahn MD, Warde P, Marzouk S (2017) Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer. Cancer 123(2):237–244PubMedCrossRef
14.
Zurück zum Zitat Hoogland AI, Nelson AM, Small BJ, Hyland KA, Gonzalez BD, Booth-Jones M, Anasetti C, Jacobsen PB, Jim HS (2017) The role of age in neurocognitive functioning among adult allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 23(11):1974–1979PubMedPubMedCentralCrossRef Hoogland AI, Nelson AM, Small BJ, Hyland KA, Gonzalez BD, Booth-Jones M, Anasetti C, Jacobsen PB, Jim HS (2017) The role of age in neurocognitive functioning among adult allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 23(11):1974–1979PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Simó M, Root JC, Vaquero L, Ripollés P, Jové J, Ahles T, Navarro A, Cardenal F, Bruna J, Rodríguez-Fornells A (2015) Cognitive and brain structural changes in a lung cancer population. J Thorac Oncol 10(1):38–45PubMedPubMedCentralCrossRef Simó M, Root JC, Vaquero L, Ripollés P, Jové J, Ahles T, Navarro A, Cardenal F, Bruna J, Rodríguez-Fornells A (2015) Cognitive and brain structural changes in a lung cancer population. J Thorac Oncol 10(1):38–45PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Vardy JL, Dhillon HM, Pond GR, Rourke SB, Bekele T, Renton C, Dodd A, Zhang H, Beale P, Clarke S (2015) Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol 33(34):4085–4092PubMedPubMedCentralCrossRef Vardy JL, Dhillon HM, Pond GR, Rourke SB, Bekele T, Renton C, Dodd A, Zhang H, Beale P, Clarke S (2015) Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol 33(34):4085–4092PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Wefel JS, Vidrine DJ, Marani SK, Swartz RJ, Veramonti TL, Meyers CA, Hoekstra HJ, Hoekstra-Weebers JE, Gritz ER (2014) A prospective study of cognitive function in men with non-seminomatous germ cell tumors. Psycho-oncology 23(6):626–633PubMedCrossRef Wefel JS, Vidrine DJ, Marani SK, Swartz RJ, Veramonti TL, Meyers CA, Hoekstra HJ, Hoekstra-Weebers JE, Gritz ER (2014) A prospective study of cognitive function in men with non-seminomatous germ cell tumors. Psycho-oncology 23(6):626–633PubMedCrossRef
18.
Zurück zum Zitat Ahles TA, Root JC, Ryan EL (2012) Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol 30(30):3675–3686PubMedPubMedCentralCrossRef Ahles TA, Root JC, Ryan EL (2012) Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol 30(30):3675–3686PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C (2012) Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38(7):926–934PubMedCrossRef Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C (2012) Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38(7):926–934PubMedCrossRef
20.
Zurück zum Zitat Koppelmans V, Breteler M, Boogerd W, Seynaeve C, Gundy C, Schagen S (2012) Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol 30(10):1080–1086PubMedCrossRef Koppelmans V, Breteler M, Boogerd W, Seynaeve C, Gundy C, Schagen S (2012) Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol 30(10):1080–1086PubMedCrossRef
21.
Zurück zum Zitat Boykoff N, Moieni M, Subramanian SK (2009) Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv 3(4):223–232PubMedPubMedCentralCrossRef Boykoff N, Moieni M, Subramanian SK (2009) Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv 3(4):223–232PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Munir F, Burrows J, Yarker J, Kalawsky K, Bains M (2010) Women’s perceptions of chemotherapy-induced cognitive side affects on work ability: a focus group study. J Clin Nurs 19(9–10):1362–1370PubMedCrossRef Munir F, Burrows J, Yarker J, Kalawsky K, Bains M (2010) Women’s perceptions of chemotherapy-induced cognitive side affects on work ability: a focus group study. J Clin Nurs 19(9–10):1362–1370PubMedCrossRef
23.
Zurück zum Zitat Von Ah D, Habermann B, Carpenter JS, Schneider BL (2013) Impact of perceived cognitive impairment in breast cancer survivors. Eur J Oncol Nurs 17(2):236–241CrossRef Von Ah D, Habermann B, Carpenter JS, Schneider BL (2013) Impact of perceived cognitive impairment in breast cancer survivors. Eur J Oncol Nurs 17(2):236–241CrossRef
24.
Zurück zum Zitat Beck JS (2011) Cognitive behavior therapy: basics and beyond. Guilford Press, New York Beck JS (2011) Cognitive behavior therapy: basics and beyond. Guilford Press, New York
28.
Zurück zum Zitat Ferguson RJ, Sigmon ST, Pritchard AJ, LaBrie SL, Goetze RE, Fink CM, Garrett AM (2016) A randomized trial of videoconference-delivered cognitive behavioral therapy for survivors of breast cancer with self-reported cognitive dysfunction. Cancer 122(11):1782–1791. https://doi.org/10.1002/cncr.29891 PubMedCrossRef Ferguson RJ, Sigmon ST, Pritchard AJ, LaBrie SL, Goetze RE, Fink CM, Garrett AM (2016) A randomized trial of videoconference-delivered cognitive behavioral therapy for survivors of breast cancer with self-reported cognitive dysfunction. Cancer 122(11):1782–1791. https://​doi.​org/​10.​1002/​cncr.​29891 PubMedCrossRef
35.
Zurück zum Zitat Wu LM, Amidi A, Tanenbaum ML, Winkel G, Gordon WA, Hall SJ, Bovbjerg K, Diefenbach MA (2018) Computerized cognitive training in prostate cancer patients on androgen deprivation therapy: a pilot study. Support Care Cancer 26(6):1917–1926PubMedCrossRef Wu LM, Amidi A, Tanenbaum ML, Winkel G, Gordon WA, Hall SJ, Bovbjerg K, Diefenbach MA (2018) Computerized cognitive training in prostate cancer patients on androgen deprivation therapy: a pilot study. Support Care Cancer 26(6):1917–1926PubMedCrossRef
36.
Zurück zum Zitat Ercoli LM, Petersen L, Hunter AM, Castellon SA, Kwan L, Kahn-Mills BA, Embree LM, Cernin PA, Leuchter AF, Ganz PA (2015) Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. Psychooncology 24(11):1360–1367. https://doi.org/10.1002/pon.3769 PubMedCrossRef Ercoli LM, Petersen L, Hunter AM, Castellon SA, Kwan L, Kahn-Mills BA, Embree LM, Cernin PA, Leuchter AF, Ganz PA (2015) Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. Psychooncology 24(11):1360–1367. https://​doi.​org/​10.​1002/​pon.​3769 PubMedCrossRef
37.
39.
Zurück zum Zitat Mihuta M, Green H, Shum D (2018) Efficacy of a web-based cognitive rehabilitation intervention for adult cancer survivors: a pilot study. Eur J Cancer Care 27(2):e12805CrossRef Mihuta M, Green H, Shum D (2018) Efficacy of a web-based cognitive rehabilitation intervention for adult cancer survivors: a pilot study. Eur J Cancer Care 27(2):e12805CrossRef
44.
Zurück zum Zitat Cicerone KD, Azulay J, Trott C (2009) Methodological quality of research on cognitive rehabilitation after traumatic brain injury. Arch Phys Med Rehabil 90(11):S52–S59PubMedCrossRef Cicerone KD, Azulay J, Trott C (2009) Methodological quality of research on cognitive rehabilitation after traumatic brain injury. Arch Phys Med Rehabil 90(11):S52–S59PubMedCrossRef
45.
Zurück zum Zitat Cicerone KD, Langenbahn DM, Braden C, Malec JF, Kalmar K, Fraas M, Felicetti T, Laatsch L, Harley JP, Bergquist T (2011) Evidence-based cognitive rehabilitation: updated review of the literature from 2003 through 2008. Arch Phys Med Rehabil 92(4):519–530PubMedCrossRef Cicerone KD, Langenbahn DM, Braden C, Malec JF, Kalmar K, Fraas M, Felicetti T, Laatsch L, Harley JP, Bergquist T (2011) Evidence-based cognitive rehabilitation: updated review of the literature from 2003 through 2008. Arch Phys Med Rehabil 92(4):519–530PubMedCrossRef
46.
Zurück zum Zitat Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52(6):377–384PubMedPubMedCentralCrossRef Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52(6):377–384PubMedPubMedCentralCrossRef
47.
Zurück zum Zitat Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928PubMedPubMedCentralCrossRef Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Milbury K, Chaoul A, Biegler K, Wangyal T, Spelman A, Meyers C, Arun B, Palmer J, Taylor J, Cohen L (2013) Tibetan sound meditation for cognitive dysfunction: results of a randomized controlled pilot trial. Psycho-Oncology 22(10):2354–2363PubMedPubMedCentral Milbury K, Chaoul A, Biegler K, Wangyal T, Spelman A, Meyers C, Arun B, Palmer J, Taylor J, Cohen L (2013) Tibetan sound meditation for cognitive dysfunction: results of a randomized controlled pilot trial. Psycho-Oncology 22(10):2354–2363PubMedPubMedCentral
49.
Zurück zum Zitat Strauss E, Sherman EM, Spreen O (2006) A compendium of neuropsychological tests: administration, norms, and commentary. American Chemical Society, Washington Strauss E, Sherman EM, Spreen O (2006) A compendium of neuropsychological tests: administration, norms, and commentary. American Chemical Society, Washington
50.
Zurück zum Zitat Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198PubMedCrossRef Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198PubMedCrossRef
51.
Zurück zum Zitat Randolph C (1998) Repeatable battery for the assessment of neuropsychological status manual. The Psychological Corporation, San Antonio Randolph C (1998) Repeatable battery for the assessment of neuropsychological status manual. The Psychological Corporation, San Antonio
53.
Zurück zum Zitat Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Erlbaum, Hillsdale Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Erlbaum, Hillsdale
55.
Zurück zum Zitat Morris SB (2008) Estimating effect sizes from pretest-posttest-control group designs. Organ Res Methods 11(2):364–386CrossRef Morris SB (2008) Estimating effect sizes from pretest-posttest-control group designs. Organ Res Methods 11(2):364–386CrossRef
56.
Zurück zum Zitat Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Nat l Cancer Inst 85(5):365–376CrossRef Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Nat l Cancer Inst 85(5):365–376CrossRef
57.
Zurück zum Zitat Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579PubMedCrossRef Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579PubMedCrossRef
58.
Zurück zum Zitat Devins GM (2010) Using the illness intrusiveness ratings scale to understand health-related quality of life in chronic disease. J Psychosom Res 68(6):591–602PubMedCrossRef Devins GM (2010) Using the illness intrusiveness ratings scale to understand health-related quality of life in chronic disease. J Psychosom Res 68(6):591–602PubMedCrossRef
59.
Zurück zum Zitat Catt S, Starkings R, Shilling V, Fallowfield L (2017) Patient-reported outcome measures of the impact of cancer on patients’ everyday lives: a systematic review. J Cancer Surviv 11(2):211–232PubMedCrossRef Catt S, Starkings R, Shilling V, Fallowfield L (2017) Patient-reported outcome measures of the impact of cancer on patients’ everyday lives: a systematic review. J Cancer Surviv 11(2):211–232PubMedCrossRef
60.
Zurück zum Zitat Goedendorp MM, Knoop H, Gielissen MF, Verhagen CA, Bleijenberg G (2014) The effects of cognitive behavioral therapy for postcancer fatigue on perceived cognitive disabilities and neuropsychological test performance. J Pain Symptom Manag 47(1):35–44CrossRef Goedendorp MM, Knoop H, Gielissen MF, Verhagen CA, Bleijenberg G (2014) The effects of cognitive behavioral therapy for postcancer fatigue on perceived cognitive disabilities and neuropsychological test performance. J Pain Symptom Manag 47(1):35–44CrossRef
61.
Zurück zum Zitat Kucherer S, Ferguson RJ (2017) Cognitive behavioral therapy for cancer-related cognitive dysfunction. Curr Opin Support Palliat Care 11(1):46–51PubMedPubMedCentralCrossRef Kucherer S, Ferguson RJ (2017) Cognitive behavioral therapy for cancer-related cognitive dysfunction. Curr Opin Support Palliat Care 11(1):46–51PubMedPubMedCentralCrossRef
62.
Zurück zum Zitat Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12(7):703–708PubMedCrossRef Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12(7):703–708PubMedCrossRef
63.
Zurück zum Zitat Downie FP, Mar Fan HG, Houédé-Tchen N, Yi Q, Tannock IF (2006) Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psycho-Oncology 15(10):921–930PubMedCrossRef Downie FP, Mar Fan HG, Houédé-Tchen N, Yi Q, Tannock IF (2006) Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psycho-Oncology 15(10):921–930PubMedCrossRef
64.
65.
Zurück zum Zitat Mlinac ME, Feng MC (2016) Assessment of activities of daily living, self-care, and independence. Arch Clin Neuropsychol 31(6):506–516PubMedCrossRef Mlinac ME, Feng MC (2016) Assessment of activities of daily living, self-care, and independence. Arch Clin Neuropsychol 31(6):506–516PubMedCrossRef
66.
Zurück zum Zitat Turner-Stokes L (2009) Goal attainment scaling (GAS) in rehabilitation: a practical guide. Clin Rehabil 23(4):362–370PubMedCrossRef Turner-Stokes L (2009) Goal attainment scaling (GAS) in rehabilitation: a practical guide. Clin Rehabil 23(4):362–370PubMedCrossRef
67.
Zurück zum Zitat Sleight A (2016) Coping with cancer-related cognitive dysfunction: a scoping review of the literature. Disabil Rehabil 38(4):400–408PubMedCrossRef Sleight A (2016) Coping with cancer-related cognitive dysfunction: a scoping review of the literature. Disabil Rehabil 38(4):400–408PubMedCrossRef
68.
Zurück zum Zitat Janelsins MC, Peppone LJ, Heckler CE, Kesler SR, Sprod LK, Atkins J, Melnik M, Kamen C, Giguere J, Messino MJ (2016) YOCAS©® yoga reduces self-reported memory difficulty in cancer survivors in a nationwide randomized clinical trial: investigating relationships between memory and sleep. Integr Cancer Ther 15(3):263–271PubMedCrossRef Janelsins MC, Peppone LJ, Heckler CE, Kesler SR, Sprod LK, Atkins J, Melnik M, Kamen C, Giguere J, Messino MJ (2016) YOCAS©® yoga reduces self-reported memory difficulty in cancer survivors in a nationwide randomized clinical trial: investigating relationships between memory and sleep. Integr Cancer Ther 15(3):263–271PubMedCrossRef
Metadaten
Titel
Cognitive rehabilitation for cancer-related cognitive dysfunction: a systematic review
verfasst von
Holly A. Fernandes
Nadine M. Richard
Kim Edelstein
Publikationsdatum
30.05.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2019
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-04866-2

Weitere Artikel der Ausgabe 9/2019

Supportive Care in Cancer 9/2019 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.